Concepedia

Author

Xiuwen Wang

Qilu Hospital of Shandong UniversityORCID

Also Known As

Feng Wang, Jisheng Li, Tianshu Liu, Wang Xiuwen, Wang,Xiaodong, Weibo Wang, X W Wang, X Wang, X-W Wang, XIUWEN WANG

313

Publications

7.6K

Citations

46

H-Index

124

Concepts

All Affiliations

Qilu Hospital of Shandong UniversityChinese Academy of Medical Sciences & Peking Union Medical CollegeShandong First Medical UniversityPeking Union Medical College HospitalFirst Affiliated Hospital of Xi'an Jiaotong University
XW

About

Xiuwen Wang is an author at Qilu Hospital of Shandong University specializing in medicine, cancer research, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

33

2.1K

2

Health Sciences

11

11

822

3

Natural Sciences

5

5

211

4

Biochemistry

5

5

130

5

Engineering

4

4

119

Xiuwen Wang

×

109

Publications

6.1K

Citations

44

H-Index

YearCitations

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang,

JAMA Oncology

2018

591

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Zhihao Lü, Junye Wang, Yongqian Shu,

BMJ

2022

438

Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells

Ying Teng, Xiuwen Wang, Yawei Wang,

Biochemical and Biophysical Research Communications

2010

247

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

Yuankai Shi, Junling Li, Shucai Zhang,

PLoS ONE

2015

200

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Zhiwei Zhou,

The Lancet Oncology

2020

182

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Chunmei Bai,

The Lancet Oncology

2020

179

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li,

Journal of Clinical Oncology

2022

161

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Jinwan Wang, Yan Sun, Qitao Yu,

PubMed

2005

147

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan,

Nature Communications

2022

147

Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation

Ying Sun, Yunshan Wang, Cong Fan,

Molecular Cancer

2014

141

Page 1